Q1 2021

Source filing unavailable

Q1 2021 · —

Revenue—

Net Income

-$3.85M

N/M vs Q1 2020

EPS, diluted—

Operating Income-$3,008,256—

Operating Cash Flow-$4,208,673—

Free Cash Flowderived-$4,248,193—

Same quarter

Metric	Q1 2021	Q1 2020
Net Income	-$3.85M	-$4.39M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

MiNK Therapeutics, Inc. · CIK 1840229 · Engraved from SEC EDGAR